Clinical Trial Detail

NCT ID NCT03041688
Title KRT-232 (AMG-232) and Decitabine in Treating Patients With Relapsed, Refractory, or Newly-Diagnosed Acute Myeloid Leukemia
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

acute myeloid leukemia

Therapies

Decitabine + KRT-232

Age Groups: adult senior

No variant requirements are available.